Looking at your UMAP and feature plots, here's my interpretation:

---

## Overall Assessment — Mostly Clean, Some Expected Overlap

---

## Macrophages (top row)
**CD14, FCGR3A, CD33, CSF1R** all show expression concentrated in the **bottom-left cluster** (red/Macrophages on UMAP) — this looks clean and specific. No concerning spillover into T cell clusters.

---

## CD3 T Cells (row 2)
**CD3D, CD3E, CD3G, TRAC** are expressed in the **large green cluster** (CD3plus). The expression looks appropriately restricted. CD3G appears slightly lower expressed which is normal — it's the least abundant CD3 subunit in scRNA-seq.

---

## CD8 T Cells (row 3)
**CD8A and CD8B** show a **subset within the CD3 cluster** — this is expected biology, not contamination. GZMB and PRF1 show sparse punctate expression which is normal for cytotoxic effector cells — only activated/effector cells express these highly.

---

## CD4 T Cells (row 4)
**CD4** appears low/sparse — this is very common in scRNA-seq due to low transcript capture, not contamination. **IL7R** fills in nicely where CD4 is weak. **FOXP3** is appropriately rare (Tregs are a small fraction). **CCR7** marks a subset consistent with naïve/central memory.

---

## B Cells (bottom row)
This is where I'd flag a concern. **IGHG1, CD27, MS4A1, CD79A** appear to show some expression **scattered across the CD3 cluster** rather than being confined to a distinct B cell cluster. A few possibilities:

| Observation | Interpretation |
|-------------|---------------|
| No distinct B cell cluster visible on UMAP | B cells may have been excluded during clustering or are very rare in this PBMC sample |
| B cell markers in CD3 cluster | Could be **doublets** (B+T cell droplets) or low-level ambient RNA contamination |
| IGHG1 scattered | Plasma cells may be rare and dispersed — or ambient immunoglobulin RNA is common in PBMCs |

---

## Recommendations

```r
# 1. Check if B cells exist as a separate cluster
DimPlot(seurat_obj, label = TRUE)

# 2. Check doublet scores if you ran DoubletFinder
FeaturePlot(seurat_obj, features = "doublet_score")

# 3. Co-expression check — true B cells should co-express CD79A + MS4A1
# If scattered cells only express one marker, likely ambient RNA
FeaturePlot(seurat_obj,
            features = c("CD79A", "MS4A1"),
            blend = TRUE)   # shows co-expressing cells in a third color

# 4. Check ambient RNA with SoupX or examine
# the fraction of B cell markers in empty droplets
```

---

## Bottom Line

**The T cell and macrophage panels look clean.** The B cell signal is the only flag — determine whether there is a true B cell cluster elsewhere in your full UMAP, or whether these are doublets/ambient RNA before drawing conclusions.

Comparing TIL vs PBMC, here's my interpretation:

---

## Overall Assessment — TIL Looks Clean, B Cell Signal is Biologically Real Here

---

## Macrophages (row 1)
**CD14, FCGR3A, CD33, CSF1R** are tightly restricted to the **green Macrophage cluster** (bottom-left). Very clean, no spillover. Macrophages are well-separated in the TIL UMAP which helps.

---

## CD3 T Cells (row 2)
**CD3D, CD3E, CD3G, TRAC** are expressed broadly across both the **red (CD3plus) and blue (CD4) clusters** — this is correct biology. Both CD4 and CD8 T cells express CD3. Clean and expected.

---

## CD8 T Cells (row 3)
**CD8A and CD8B** are nicely restricted to the **CD3plus (red) cluster**, distinct from the CD4 (blue) cluster — this is a good clean separation. Importantly **GZMB and PRF1 are notably higher** in TIL vs PBMC which is expected — TILs are more activated/cytotoxic than peripheral T cells.

---

## CD4 T Cells (row 4)
**CD4 and IL7R** appropriately mark the **blue CD4 cluster**. **FOXP3** shows sparse expression within the CD4 cluster — consistent with a Treg subset, biologically expected in TILs. **CCR7** is appropriately low — TILs are predominantly effector/memory, not naïve, so low CCR7 is expected and correct.

---

## B Cells (bottom row)
Unlike PBMC, the B cell markers here tell a clearer story:

| Marker | Observation | Interpretation |
|--------|-------------|---------------|
| **IGHG1** | High expression in a distinct region | Plasma/plasmablast cells present in tumor |
| **CD27** | Scattered low expression | Memory B cells or T cell co-expression (CD27 is not B-cell exclusive) |
| **MS4A1** | Small distinct cluster | True B cells present as minor population |
| **CD79A** | Overlaps MS4A1 pattern | Confirms true B cells, not contamination |

**MS4A1 and CD79A co-localizing** is the key — this indicates **true B cells**, not ambient RNA. In PBMC you saw scatter; here you see a focal cluster.

---

## TIL vs PBMC Comparison — Key Differences

| Feature | PBMC | TIL | Interpretation |
|---------|------|-----|----------------|
| Macrophage markers | Clean | Clean | Both fine |
| CD8 cytotoxic markers (GZMB, PRF1) | Low/sparse | **Higher** | TILs more activated ✅ |
| CCR7 | Present | Low | TILs are effector not naïve ✅ |
| FOXP3 | Rare | Present in CD4 cluster | More Tregs in tumor ✅ |
| B cell markers | Scattered — concerning | Focal cluster | TIL B cells are real ✅ |
| CD4 transcript | Low | Low | Expected in scRNA-seq both ✅ |

---

## Bottom Line

**No concerning contamination in TIL.** The data reflects expected tumor microenvironment biology — more cytotoxic/exhausted T cells, more Tregs, resident macrophages, and a small but real B cell population. The PBMC B cell scatter was the only flag between the two datasets, and by contrast the TIL B cell signal looks focal and legitimate.

---
##recurring deg heatmap interpretation

These heatmaps show strong and interpretable directionality. Here's a full breakdown:

---

## Overall Answer — Yes, Strong Directional Consistency

The majority of genes show **blocks of uniform red or blue** across contrasts rather than mixed patterns, which means the recurrent DEGs are largely changing in the same direction across comparisons. This is a strong validation of your gene signatures.

---

## PFS Heatmap (left)

| Observation | Interpretation |
|-------------|---------------|
| **Large red block** (top cluster) | Genes consistently **upregulated in NoPrg6M vs Prg6M** — these are survival-associated genes, higher in non-progressors |
| **Large blue block** (bottom cluster) | Genes consistently **downregulated** — higher in progressors, potential resistance/progression markers |
| Mostly **Consistent UP / Consistent DOWN** in Direction bar | Very little mixed signal — directionally robust |
| Signal present across **both Baseline and Week4** | These PFS-associated genes are stable across timepoints, not timepoint-dependent artifacts |
| **CD3+ and CD4 cell types** driving most signal | T cell compartment is the primary source of PFS-associated DEGs in TIL |

**Key takeaway:** You have a clean gene signature separating non-progressors from progressors that is consistent across timepoints and T cell subsets.

---

## Treatment Heatmap (middle)

| Observation | Interpretation |
|-------------|---------------|
| **Fragmented/patchy pattern** compared to PFS | Treatment comparisons are inherently noisier — 3 pairwise contrasts (Combo vs Nivo, Combo vs Rela, Rela vs Nivo) pull in different directions |
| Some genes **red in Combo vs Nivo but blue in Rela vs Nivo** | Expected — these genes distinguish Combo from monotherapies, not a QC concern |
| **Macrophage-driven red block** (bottom) | A subset of genes is consistently upregulated in Macrophages across treatment comparisons |
| More **Mixed** in Direction bar than PFS | Reflects the multi-arm comparison structure — some genes flip depending on which treatment pair is compared |
| Timepoint (Baseline/Week4) shows some separation | Treatment effects may differ by timepoint — worth exploring per-timepoint treatment DEGs |

**Key takeaway:** Treatment DEGs are more complex due to 3-way comparisons. Focus on genes that are consistent within a specific contrast (e.g. Combo vs Nivo only) rather than across all three.

---

## Timepoint Heatmap (right)

| Observation | Interpretation |
|-------------|---------------|
| **Strong red block** (top genes) | Genes consistently **upregulated at Week4 vs Baseline** across treatment arms and cell types |
| **Strong blue block** (bottom genes) | Genes consistently **downregulated at Week4** — baseline-enriched genes |
| Very consistent across **Combo, Nivo, Rela** treatment bars | These temporal changes are **treatment-independent** — happening regardless of which drug |
| **CD3+ dominant** in CellType bar | T cells are the primary responders to treatment over time in TIL |
| Mostly **Consistent UP/DOWN** in Direction bar | Strongest directionality of the three plots |

**Key takeaway:** The timepoint heatmap shows the clearest and most consistent directionality — these are robust temporal response genes that change from Baseline to Week4 regardless of treatment arm.

---

## Cross-Heatmap Comparison

| | PFS | Treatment | Timepoint |
|--|-----|-----------|-----------|
| Directionality | ✅ Strong | ⚠️ Moderate | ✅ Strongest |
| Consistency across contrasts | ✅ High | ⚠️ Mixed | ✅ Very high |
| Primary cell type | CD3+/CD4 | Macrophages + T cells | CD3+ |
| Biological interpretation | Survival signature | Drug-specific effects | Universal treatment response |
| Mixed direction genes | Few | More | Few |

---

## What to Do Next

```r
# 1. Extract the consistent UP/DOWN genes from each plot for pathway analysis
consistent_up   <- rownames(direction_df)[direction_df$Direction == "Consistent UP"]
consistent_down <- rownames(direction_df)[direction_df$Direction == "Consistent DOWN"]

# 2. Run pathway enrichment on each directional gene set
library(clusterProfiler)
ego_up <- enrichGO(gene = consistent_up, OrgDb = org.Hs.eg.db,
                   keyType = "SYMBOL", ont = "BP")

# 3. Overlap PFS and Timepoint consistent genes — 
# genes changing over time AND associated with outcomes are high priority
overlap_genes <- intersect(pfs_consistent, timepoint_consistent)
cat("Genes recurrent in both PFS and Timepoint:", length(overlap_genes), "\n")
print(overlap_genes)
```

The overlap between PFS-consistent and Timepoint-consistent genes would be particularly high-value candidates — genes that both change with treatment over time **and** associate with clinical outcome.

Comparing directly to TIL, here's the full PBMC interpretation:

---

## Overall Answer — Directionality is Present but Weaker and Noisier Than TIL

The PBMC heatmaps show more fragmented, patchy patterns compared to TIL's clean blocks. This is **biologically expected** — peripheral blood reflects systemic immune state while TIL captures the local tumor response which is more coherent.

---

## PFS Heatmap (left)

| Observation | Interpretation |
|-------------|----------------|
| **Fragmented red/blue pattern** rather than clean blocks | PFS signal in PBMC is weaker and less consistent than TIL |
| Some **consistent UP genes** visible in upper cluster | A subset of non-progressor-associated genes exists in peripheral blood |
| **Large blue region** in lower cluster | Progressor-enriched genes present in PBMC — but less coherent than TIL |
| **More yellow/Mixed** in Direction bar than TIL | More genes flip direction depending on timepoint or cell type |
| Signal concentrated in **CD3+ and CD4** again | T cells dominate PFS signal in both compartments |
| Baseline vs Week4 **drives some of the patchiness** | Some PFS genes are only significant at one timepoint in PBMC |

**Key takeaway vs TIL:** The PFS signature is **detectable but diluted** in PBMC. Fewer genes are consistently directional, suggesting the tumor microenvironment captures outcome-associated biology better than peripheral blood for this dataset.

---

## Treatment Heatmap (middle)

| Observation | Interpretation |
|-------------|----------------|
| **Strongest signal of the three PBMC plots** | Treatment effects are actually more visible in PBMC than PFS or timepoint |
| **Large coherent red block** | Strong consistent upregulation in one treatment arm — likely Combo |
| **Large coherent blue block** | Consistent downregulation in another arm |
| More **Consistent UP/DOWN** than PBMC PFS | Treatment comparisons are cleaner in blood than outcome comparisons |
| **Macrophages contribute** visible signal | Monocyte/macrophage response to treatment detectable in peripheral blood |
| Timepoint bar shows **Baseline dominates** | Treatment differences most pronounced at Baseline — may reflect patient stratification rather than drug effect |

**Key takeaway:** PBMC treatment DEGs are surprisingly coherent — possibly reflecting **pre-treatment immune differences** between patients assigned to different arms rather than direct drug effects.

---

## Timepoint Heatmap (right)

| Observation | Interpretation |
|-------------|----------------|
| **Patchy, fragmented pattern** | Weakest directionality of the three PBMC plots |
| Some red clusters at top | A subset of genes consistently rises from Baseline to Week4 in blood |
| **Inconsistent across treatment arms** | Unlike TIL where timepoint changes were treatment-independent, PBMC temporal changes vary by treatment arm |
| More **Mixed** genes than TIL timepoint | Blood gene expression changes are more treatment-dependent |
| **CD3+ dominant** again | T cells still the primary signal source |

**Key takeaway vs TIL:** TIL showed universal treatment-independent temporal changes. PBMC temporal changes are **treatment-arm dependent** — suggesting the peripheral response to treatment is not uniform across Combo, Nivo and Rela.

---

## PBMC vs TIL Side-by-Side

| | PBMC PFS | TIL PFS | PBMC Treatment | TIL Treatment | PBMC Timepoint | TIL Timepoint |
|--|----------|---------|----------------|---------------|----------------|---------------|
| Directionality | ⚠️ Weak | ✅ Strong | ✅ Moderate | ⚠️ Complex | ❌ Weakest | ✅ Strongest |
| Consistency | ⚠️ Patchy | ✅ Clean blocks | ✅ Coherent | ⚠️ Mixed | ⚠️ Variable | ✅ Uniform |
| Mixed genes | More | Few | Moderate | More | Most | Few |
| Best signal | — | PFS + Timepoint | Treatment | — | — | Timepoint |
| Biological meaning | Diluted outcome signal | Tumor outcome signature | Pre-treatment stratification? | Drug-specific effects | Treatment-arm dependent | Universal response |

---

## Key Biological Conclusions Across Both Tissues

**1. TIL is the stronger compartment** for outcome-associated (PFS) and temporal gene signatures — the tumor microenvironment captures disease biology more directly.

**2. PBMC treatment signal** is surprisingly strong and may reflect **patient immune stratification at baseline** rather than drug response — worth checking if Baseline-only treatment DEGs overlap with PFS genes.

**3. The genes that are consistent in BOTH PBMC and TIL** across any category are your highest-confidence candidates:

```r
# Find genes consistent in both compartments
pbmc_consistent <- rownames(pbmc_direction_df)[
  pbmc_direction_df$Direction %in% c("Consistent UP", "Consistent DOWN")]

til_consistent <- rownames(til_direction_df)[
  til_direction_df$Direction %in% c("Consistent UP", "Consistent DOWN")]

# Overlap — highest priority genes
shared_consistent <- intersect(pbmc_consistent, til_consistent)
cat("Shared consistent DEGs across PBMC and TIL:", length(shared_consistent), "\n")
print(shared_consistent)
```

These shared genes represent biology that is **detectable in both the tumor and periphery** — the strongest candidates for biomarker development or mechanistic follow-up.